| Literature DB >> 30425536 |
Effat Davoudi-Monfared1, Hossein Khalili1.
Abstract
Data on the status of carbapenem-resistant microorganisms in the Middle East countries are scarce. The aim of this review was to collect available data regarding resistance to carbapenems in a Middle East region. Available data regarding carbapenem-resistant isolates were considered for evaluation in this review. Biomedical electronic databases were systematically searched to find related articles. The key terms used were "carbapenem-resistant, resistant gram-negative bacilli, Enterobacteriaceae, fermenting and non-fermenting gram-negative bacilli, Pseudomonas, Acinetobacter, Klebsiella and Iran". After primary screening, 275 relevant articles were selected to be assessed thoroughly. Resistance rate to carbapenems was reported between 1% and 86% during years 2006-2018. Most of the carbapenem-resistant microorganisms were isolated from burn patients. Modified Hodge test was a commonly used phenotypic test. Only in few studies, genotypic assays were considered. Pattern of antibiotic use can affect emergence of resistant microorganisms. Rational use of drugs, and specifically, antibiotics is a challenging issue in developing countries. Mean number of drugs per prescription in these countries was higher than the World Health Organization standards. Overuse of antibiotics, especially injectable ones, and easy access to antibiotics without prescription is a warning alarm for future antibiotic resistance in developing countries. Establishing antimicrobial stewardship's programs is new in the hospitals. Unfortunately, rules and regulatory issues to restrict antibiotic access in community pharmacies and prescription by general physicians are limited.Entities:
Keywords: antibiotics; carbapenem; gram-negative bacteria; resistant
Year: 2018 PMID: 30425536 PMCID: PMC6203168 DOI: 10.2147/IDR.S176049
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Screening methods for carbapenem-resistant microorganisms.
Notes: 1MHT was the most used phenotypic method in Iranian studies. MHT originally detects KPC, but if zinc sulfate is added to MHT culture media, it can detect MBL.2 It is based on carbapenemase inhibition by betalactamase inhibitors. CDT consists of two disks: a carbapenem and the other combination of a carbapenem and a betalactamase inhibitor. If the disk with inhibitor shows a bigger inhibition zone, the result is considered positive. DDST consists of carbapenem discs at a variable distance to inhibitor discs. The observation of synergy between disks is noted as a positive result. 3These phenotypic methods can detect different Ambler classes. 4CIM is a newer phenotypic method that was introduced in 2015 by van der Zwaluw. A carbapenem disk is inserted in culture media of suspected strain. Then it is transferred to another culture media with known control strain. If the suspected strain contains carbapenemase enzyme, the carbapenem disk has been degraded and the control strain in second culture will grow. 5Some other phenotypic methods like spectrometric assays are also used and have higher sensitivity and specificity, but they are costly and time consuming.
Abbreviations: CDT, combination disk test; CIM, carbapenem inactivation method; DDST, double disk synergy test; ESBL, extended spectrum β-lactamase; KPC, Klebsiella-producing carbapenemase; MBL, metallo-β-lactamase; MHT, modified Hodge test; MIC, minimum inhibitory concentration; PCR, polymerase chain reaction.
Figure 2Consort flowchart of study.
Abbreviation: ESBL, extended spectrum β-lactamase.
Screening of carbapenem-resistant isolates (disk diffusion method)
| Author (year) | Setting | Population | Samples | Microorganism (No.) | MIC | Resistance rate to FQ and AG | Results | Weak points | Strength points |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Mobaraki et al (2018) | Hospitals in Tabriz | Inpatients and outpatients | Different sites | – | TOB 57% | • 46.5% of isolates were resistant to IPM | – | • Multicenter study | |
| Ghanbari et al (2017) | One hospital in Fuldshahr | General inpatients | Urine | Different strains (317) | – | c | • 9.5% of | – | • Large sample size |
| Chahoofard et al (2017) | One hospital in Bandar Abbas | General inpatients | Urine | Different strains (296) | – | c | • Resistance rate to IPM: | – | • Adequate sample size |
| Ansari et al (2017) | Two hospitals in Shahrekord | General inpatients | Urine, blood, sputum, wound | – | NAL 80%, OFX 86 % LVX 66 % | • About 55% of strains were resistant to IPM and DOR | • Small sample size | • Cloning smpA gen | |
| Douraghi et al (2016) | Four hospitals in Tehran | General inpatients and outpatients | Different sites | ✓ | – | • 97% were resistant to carbapenems | – | • Multicenter study | |
| Ghasemian et al (2016) | Four hospitals in Mazandaran | General ICU patients | Different sites | ✓ | CIP 96% AMK 100% | • Resistance to IPM and MEM according to E-test was 100%, and according to disk diffusion was 76% and 96%, respectively | • Small sample size | • Multicenter study | |
| Babamahmoodiet al (2015) | Three hospitals in Mazandaran | ICU patients | Wound, respiratory secretions, urine, blood | Different strains (114) | – | c | • 14% of | • Small sample size for each strain | • Multicenter study |
| Mohajeri et al (2014) | Three hospitals in Kermanshah | General inpatients | Blood, urine, sputum | – | Not defined | • 48% of isolates were resistant to carbapenems (imipenem and meropenem). 76% of carbapenem-resistant strains were isolated from sputum samples | • Few antibiotics were tested | • Multicenter study | |
| Babakhani et al (2014) | One hospital in Khorramabad | General inpatients (mostly ICU) | Different sites | – | GEN 52 % AMK 7.5% CIP 82 % OFX 75% NAL 60% | • 67% and 1% of isolates were resistant to IMP and MEM, respectively | – | ||
| Kamalbeik et al (2013) | One Poisoning center in Tehran | ICU patients | Different sites | – | CIP 97% | • Resistance rates to MEM and IPM were 100% and 62% (27.5% intermediate resistant to IPM) | • Small sample size | – | |
| Hashemi et al (2013) | Two hospitals in Hamadan | General inpatients and outpatients | Different sites | – | c | • Resistance rate to IPM was 32% in inpatients and 4% in outpatients. Resistance rates to IPM in inpatients: | – | • Large sample size | |
| Shakibaie et al (2012) | One hospital in Kashan | ICU patients | Different sites | ✓ | CIP 60% GEN 60% AMK 26% | • 73% of isolates were resistant to IPM | • Very small sample size | – | |
| Rahbar et al (2010) | One hospital in Tehran | General inpatients | Different sites | – | c | • 1 %, 16%, and 98% of | – | • Demographic and medical data of patients were provided | |
| Soroush et al (2010) | One pediatric hospital in Tehran | General pediatric patients | Different sites | – | In 2007: CIP 79% AMK 58% KAN 71% GEN 65% TOB 61% | • Resistance rate to IPM and MEM was analyzed in years 2006 and 2007 that was about 50% | • Carbapenem resistance was evaluated only in the last 2 years (2006–2007) | • Evaluated carbapenem resistance status in pediatrics | |
| Yousefi et al (2010) | One hospital in Orumie | General inpatients and outpatients | Different sites | ✓ | – | • Approximately 40% of isolates were resistant to IPM, which means MIC for them was 31 mcg/mL | • Just IPM was tested | – | |
| Rahbar et al (2008) | One hospital in Tehran | General inpatients and ICU patients | Not defined | Different strains (202) | ✓ | • 40% and 7% of | – | ||
Notes:
MIC values of carbapenems (and not other antimicrobial agents) were determined.
Resistant rates were reported according to the disk diffusion test. The unit for all reported MIC values is mcg/mL.
For complete information about the resistance to AG and FQ, refer to the original reference.
Abbreviations: AG, aminoglycoside; AMK, amikacin; CDT, combination disk test; CIP, ciprofloxacin; DD, disk diffusion; DDST, double disk synergy test; DOR, doripenem; ERT, ertapenem; ESBL, extended spectrum β-lactamase; FQ, fluoroquinolones; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; KAN, kanamycin; LVX, levofloxacin; MBL, metallo-β-lactamase; MEM, meropenem; MHT, modified Hodge test; MIC, minimum inhibitory concentration; NAL, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; TOB, tobramycin.
Studies that considered phenotypic methods for detecting carbapenemase enzymes
| Author (year) | Setting | Population | Samples | Microorganism (no.) | MIC | Method of carbapenemase detection | Resistance to FQ and AG | Results | Weak points | Strength points |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Ghotaslou et al (2018) | Five hospitals in East and West Azerbaijan | General inpatients | Different sites | – | • DD | • Resistance rate to carbapenem was observed only in | • Small sample size for each species | – | ||
| Saadatian Farivar et al (2018)27 | Three hospitals in Tehran | Inpatients and outpatients | Different sites | – | • DD | OFX 65%, CIP 68%, NOR 66%, GEN 66%, AMK 51%, TOB 56 %, KAN 79%, GEN 96% | • Resistance rate to IPM was 45% | – | – | |
| Moosavian et al (2014) | Two hospitals in Ahvaz | General inpatients | Different sites | – | • DD | AMK 96% CIP 98% | • Resistance rates to IPM, MEM, and ERT were 95%, 96%, and 53%, respectively | – | – | |
| Jonaidi Jafari et al (2014) | One hospital in Tehran | General inpatients | Different sites | Different strains (350) | ✓ | • DD | – | • MIC was determined by E-test | • Small sample size for each microorganism | – |
| Ghadiri et al (2014) | Three laboratories in Tehran | General outpatients | Urine | • DD | AMK 11% | • 67 isolates were ESBL producers and resistance to carbapenem in this group was about 10% | – | • Large sample size | ||
| Fazeli et al (2014) | Teaching hospitals in Isfahan | General inpatients and ICU patients | Different sites | – | • DD | Resistance rate to GEN and AMK and CIP: 70%–80% LVX: 50%–60% | • Resistance rates to IPM, MEM, and ERT among all strains were 57%, 52%, and 47%, respectively | • It is not clear that the study was multicenter or not | – | |
| Mirsalehian et al (2014) | Motahari hospital | Burn patients | Probably burn wounds | ✓ | • DD | – | • All IPM-resistant | – | – | |
| Moayednia et al (2014) | One hospital in Isfahan | General inpatients and outpatients | Urine | • DD | Just reported for ESBL producer | • Resistance rate to carbapenem for | • MIC was done by E-test, but cutoffs were not reported | • Large sample size | ||
| Erfani et al (2013) | Three hospitals in Tehran | General inpatients | Different sites | – | • DD | CIP 95% | • Resistance rate to IPM and MEM was about 95% and 92% of these resistant isolates were MBL positive | – | – | |
| Lari et al (2013) | One hospital in Tehran (Motahhari) | Burn patients | Mostly burn wound | – | • SDDT for ESBL detection | GEN 64.7% | • Resistance rate to IPM was 92% • ESBL was positive in 10% of isolates | – | • Mortality rate was reported | |
| Rastegar Lari et al (2013) | One hospital in Tehran (Motahari) | Burn patients | Burn wounds | – | • DD | AMK 71% | • Resistance rate to IPM was 54% and all were KPC producers | • FQ and colistin were not tested | • Mortality rate was reported | |
| Safari et al (2013) | Three educational hospitals in Hamadan | ICU patients | Trachea, blood, urine, sputum, wounds | ✓ | • DD | Resistant: CIP 97% | • Resistance rate to carbapenem was 85%–94% but according to MIC, it was 87%–99% | • Multicenter study | ||
| Masaeli et al (2012) | Two hospitals in Sanandaj | General inpatients | Different sites | Different strains (423) | – | • DD | GEN 70% | • The result of disk diffusion for carbapenem was not reported | • The resistance pattern of each group of microorganisms was not fully defined | • Correlation between being MBL and different clinical risk factors was assessed |
| Japoni-Nejad et al (2013) | One hospital in Arak | General inpatients and environmental isolates | Different strains | ✓ | • MHT for KPC detection | Amikacin 80% | • 84% were resistant to carbapenem | • Isolates from environment of hospital were also included | • Small sample size | |
| Haji Hashemi et al (2012) | Different hospitals in Tehran and Isfahan | General inpatients and outpatients | Different sites | – | • DD | – | • MHT and CHROMagar were compared | • MIC was not reported | • Multicenter study | |
| Azimi et al (2012) | Two burn hospitals in Tehran | Infant and pediatric patients | Not defined (probably burn wounds) | – | • DD | Not defined | • 36 isolates were resistant to all tested antibiotic (not mentioned which antibiotics) except Colistin | • Types of samples were not defined | ||
| Japoni et al (2006) | One hospital in Shiraz | General inpatients | Different sites (mostly wound) | ✓ | • DD | CIP 73% | • Resistance rate to carbapenems was 33% | • Small sample size | ||
Notes:
MIC values for carbapenems (but not other antimicrobial agents) were determined.
Resistance rates were according to the result of disk diffusion test.
For complete information about the resistance to AG and FQ, please refer to the original reference.
Abbreviations: AG, aminoglycoside; AMK, amikacin; BA, boronic acid; CDT, combination disk test; CIP, ciprofloxacin; DD, disk diffusion; DDST, double disk synergy test; DOR, doripenem; DPA, dipicolinic acid; ERT, ertapenem; ESBL, extended spectrum β-lactamase; FQ, fluoroquinolones; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; KAN, kanamycin; KPC, Klebsiella-producing carbapenemase; LVX, levofloxacin; MBL, metallo-β-lactamase; MEM, meropenem; MHT, modified Hodge test; MIC, minimum inhibitory concentration; NAL, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; TOB, tobramycin.
Studies that performed genotypic methods to detect genes encoding carbapenemase enzymes
| Author (year) | Setting | Population | Samples | Microorganism (no.) | MIC | Method of carbapenemase detection | Resistance to FQ and AG | Results | Weak points | Strength points | Found carbapenemase genes |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Sharikhani et al (2017) | Four hospitals in Qom | General inpatients (mostly ICU) | Different sites | – | • DD | CIP and AMK 93% | • 89% isolates were non-susceptible to IPM and MEM | – | • First report of blaOXA-143 in Iran | ||
| Mohammadi et al (2017) | Two hospitals in Tehran | General inpatients | Burn wound and trachea | – | • DD | – | • About 90% of isolates were resistant to carbapenem | • Ability of biofilm formation was assessed | |||
| Bahador et al (2015) | One hospital in Tehran | Burn patients | Not defined (probably burn wounds) | ✓ | • DD | Not reported specifically | • According to MIC values, 61% were resistant to IPM | • Resistance to each antibiotic was not reported specifically | • MIC values of IPM, tigecycline, and colistin were reported | ||
| Kooti et al (2015) | Four hospitals in Shiraz | General inpatients | Different sites | – | • DD | GEN 84.5% | • About 99% of isolates were resistant to IPM and MEM | – | Multicenter study | ||
| Azizi et al (2015) | Two hospitals in Kerman | ICU patients | Different sites | ✓ | • DD | CIP 100% | • MIC values for IPM and MEM for 76% of strains were >256 mcg/mL | – | – | ||
| Mahdian et al (2015) | One hospital in Tehran (Motahari) | Burn patients | Burn wounds, blood, urine | – | • DD | CIP 100% GEN 94.6% | • 81% of strains were resistant to carbapenem | • Small sample size | • MIC values for colistin and polymyxin B were reported | ||
| Farsiani et al (2015) | One hospital in Mashhad | General inpatients and ICU patients | Different sites | ✓ | • DD | CIP 97% | • 97% of strains were resistant to carbapenems | • Small sample size | • | ||
| Nasrolahei et al (2014) | Two hospitals in Tehran and Sari | ICU and burn patients | Trachea and burn wounds | – | • DD | STP 90% GEN 83% TOB 83% KAN 80% | • Resistance rate to IPM and MEM was about 70% | • FQ are not tested | • Multicenter study | ||
| Safari et al (2014) | Three hospitals in Hamadan | ICU patients | Different sites | ✓ | • DD | AMK 19% | • Resistance rate to carbapenems was about 20% | – | |||
| Bahador et al (2014) | Two hospitals in Tehran | ICU patients | Different sites | ✓ | • DD | • Resistance rates were compared among years 2006 and 2011, according to MIC cutoffs | • Range of MIC values for each antibiotic was reported | – | |||
| Karmostaji et al (2013) | Two hospitals in Tehran | General inpatients (mostly ICU) | Different sites | – | • DD | CIP 95% | • Resistance rate to IPM and MEM were 67% and 84%, respectively | – | – | ||
| Shoja et al (2013) | Two hospitals in Ahvaz | ICU patients | Trachea | – | • DD | GEN 83%, TOB 78%, AMK 88%, CIP 96%, | • Resistance rate to IPM and MEM was 96% | – | – | ||
| Sohrabi et al (2012) | One hospital in Tabriz | General inpatients | Different sites | • DD | CIP and GEN 86% | • 62% of isolates were resistant to carbapenems | – | – | |||
| Sepehriseresht et al (2012) | One hospital in Tehran (Motahari) | Burn patients | Burn wounds | – | • DD | – | • 56% of isolates were resistant to IPM, although 13% intermediate resistance should be considered | • Origin of | – | ||
| Forozesh Fard et al (2012) | One hospital in Isfahan | CF patients | Sputum | – | • DD | CIP 0% | • None of the isolates was resistant to IPM. None was positive for | • Very small sample size | – | – | |
| Peymani et al (2012) | One hospital in Tabriz | General inpatients | Different sites | – | • PCR | – | • All IPM-resistant isolates were chosen for study | – | – | ||
| Asadollahi et al (2012) | One teaching hospital in Tehran | ICU burn patients | Burn wounds | ✓ | • DD | CIP 100% | • Resistance rate to IPM was 48% | Small sample size | • MIC values were reported for each antibiotic | ||
| Taherikalani et al (2009) | Six hospitals in Tehran | General impatients | Different sites | ✓ | • DD • PCR • Clonal typing | – | • 52% of isolates were carbapenem resistant • MIC50 range for carbapenem was 0.12–256 mcg/mL • Seven isolates that had MIC =256 mcg/mL had more than two | • Number of tested antibiotics were few | • Multicenter study | ||
| Feizabadi et al (2008) | One hospital in Tehran | General inpatients | Different sites | ✓ | • DD | CIP 81% | • About 50% of strains were resistant to carbapenems | ||||
| Taherikalani et al (2008)61 | Two hospitals in Tehran | Burn patients | Burn wounds | – | • DD | Resistance AMK 71% | • Resistance rate to carbapenem was about 60% | • Small sample size | |||
Notes:
Results about bla were not provided because this gene has no correlation with occurrence of resistance, unless it has ISAba genes in its upstream.
Resistance rates were according to the results of disk diffusion test.
For complete information about the resistance to AG and FQ, please refer to the original reference.
Abbreviations: AG, aminoglycoside; AMK, amikacin; CIP, ciprofloxacin; DD, disk diffusion; FQ, fluoroquinolones; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; KAN, kanamycin; LVX, levofloxacin; MEM, meropenem; MIC, minimum inhibitory concentration; NAL, nalidixic acid; PCR, polymerase chain reaction; STP, streptomycin; TOB, tobramycin; NTL, netilmicin.
Details of studies that used both phenotypic and genotypic methods for detection of carbapenemase-producing strains
| Author (year) | Setting | Population (no.) | Samples | Microorganism | MIC | Method of carbapenemase enzyme detection | Resistance to FQ and AG | Outcome | Weak points | Strength points | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Solgi et al (2017) | Two hospitals (city was not defined) | General inpatients (mostly ICU) | Rectal swab | ✓ | • MHT for MBL detection | AMK 24% | • 36 resistant strains were detected according to the phenotypic methods that among them carbapenem-resistance rates were between 88% and 100% | • MIC values were determined, but not analyzed | • Risk factors for infection with resistant strains were investigated | ||
| Khorvash et al (2017) | One hospital in Isfahan | ICU patients | Different sites | • MHT | AMK 79% | • Resistance rate to carbapenem was 97% | – | • Ratio of MDR pathogens for each sample was defined | |||
| Hosseinzadeh et al (2017) | Two hospitals in Shiraz | General inpatients and ICU patients | Different sites | ✓ | • MHT for MBL detection | AMK 78% | • 13% of isolates (29 ones) were resistant to IPM and MEM and had an MIC value of 1.5–32 mcg/mL (25 isolates had MIC ≥4 mcg/mL) | • Large sample size | |||
| Akhi et al (2017) | Seven hospitals in Tabriz and Orumie | General inpatients | Different sites | – | • DD | CIP 66% | • 49% (121) of isolates were carbapenem resistant | • MIC was not tested | • Large sample size | ||
| Falahat et al (2016) | Three hospitals in Arak | General inpatients | Different sites | – | • MHT and CDT for KPC detection | CIP 20% | • Resistance rate to carbapenem was about 25% | – | • Multicenter study | ||
| Mohammadzadeh et al (2016) | Two hospitals in Tehran | General inpatients | Not defined (probably different sites) | Different strains (864) | – | • CDT, MHT, and DDST for MBL detection | Not defined | • 7% of isolates were IPM resistant | – | • Large sample size | |
| Tarashi et al (2016) | One hospital in Tehran | Burn patients | Burn wounds | – | • CDT for MBL | In 2015 for | • Carbapenem resistance rate of | – | • Large sample size | ||
| Maspi et al (2016) | One hospital in Tehran | General inpatients and ICU patients | Different sites (mostly BAL and wounds) | – | • CDT for MBL detection | TOB 75% | • Resistance rates to MEM and IMP were 90% and 73%, respectively | • MIC was not reported | • First report of | ||
| Moghadam et al (2016) | Two hospitals in Shiraz | General inpatients and ICU patients | Different sites | ✓ | • E-test for MBL detection | AMK 69% | • Resistance to carbapenem was about 95% and according to MIC, it was 98% | – | • Results of general and ICU patients were discussed separately | ||
| Pakbaten Toupkanlou et al (2015) | One hospital in Tehran | Burn patients | Not defined | • CDT for ESBL detection | CIP 98%, AMK, GEN, and TOB 96% | • All resistant strains to IPM were chosen for study | • Small sample size | – | |||
| Bina et al (2015) | Three hospitals in Tehran | General inpatients | Different sites | – | • MHT test for KPC detection | GEN 41.3% | Resistance rate to carbapenem was 14% (41 strains) | • Few antibiotics were tested | • Large sample size | – | |
| Eftekhar and Naseh (2015) | Two hospitals in Tehran | Thirty nonburn and 25 burn patients | Different sites | – | • CDT for ESBL detection | Burn and nonburn patients respectively: CIP 84%, 60% AMK 52%, 33.3% GEN 84%, 56.7% | Resistance rates to carbapenem were 20% in burn and 0% in nonburn patients | • Small sample size | • Comparison of resistance pattern in burn and nonburn patients | – | |
| Lari et al (2015) | One hospital in Tehran | Burn patients | Burn wounds | – | • CDT for ESBL production | Were tested but not reported specifically | • All IPM-resistant strains were chosen for study | Resistance to other antibiotics was not defined clearly | • Large sample size | ||
| Bagheri Josheghani et al (2015) | One hospital in Kashan | General inpatients | Different sites | – | • CDT for ESBL detection | AMK 78% GEN 83% LVX and CIP 99% | Resistance rates to carbapenems was about 90% | – | – | ||
| Azimi et al (2016) | One hospital in Tehran | Burn patients | Burn wounds | Different strains (161) | – | • MHT and DDST for MBL detection | – | All IPM-resistant strains were included | • Exact number of resistance genes was not reported | • The sensitivity and specificity of each phenotypic test were reported | |
| Azimi et al |(2015) | One hospital in Tehran | Burn patients | Burn wounds | – | • CDT for ESBL detection | 80% of strains were resistant to all AG | All IPM-resistant strains were selected for study | – | – | ||
| Fazeli et al (2015) | One hospital in Isfahan | General inpatients | Different sites | ✓ | • MHT and E-test for MBL detection | CIP 63.4% | 42% of strains (49 isolates) were resistant to IPM and MEM | ||||
| Khoshvaght et al (2014) | Four hospitals in Zanjan | General pediatrics | Stool | – | • DDST for ESBL and MBL detection | CIP 37% | IPM resistance rate was 2.1% | • MIC was not tested | • Large sample size | ||
| Noori et al (2014) | Two hospitals in Tehran | General inpatients | Different sites | ✓ | • DD | CIP 92% | • 91% (99 isolates) were resistant to IPM and MEM | – | – | ||
| Vali et al (2014) | Two pediatric hospitals in Tehran | Cystic fibrosis inpatients | Sputum | Different gram negative (52) | ✓ | • CDT for ESBL detection | GEN 24.5% | • Resistance rate to MEM was 14% (eight strains) that MHT was positive in three of them | – | • Data provided from cystic fibrosis patients | |
| Azimi et al (2014) | One hospital in Tehran | Burn patients | Burn wounds | ✓ | • MHT | GEN 90% AMK 79% | All isolates were resistant to IPM and MEM | • Small sample size | • CarbaNP test was done | ||
| Hashemi et al (2014) | Two hospitals in Tehran | General inpatients and infants | Different sites | ✓ | • CDT | Resistance and intermediate: CIP 39.7%, 4.8% | • Resistance rates to IPM, MEM, and DOR were between 68% and 74% | – | • Detection of porin-related genes | ||
| Japoni-Nejad et al (2014) | One hospital in Arak | ICU patients | Surgical wounds, urine, blood, respiratory secretions | – | • MHT | • Resistance rate to carbapenems in Amp C producers and carbapenemase producers was 5% and 66%, respectively | – | – | |||
| Farajzadeh Sheikh et al (2014) | Hospitals in Ahvaz | General inpatients | Different sites | ✓ | • CDT and E-test for MBL detection | GEN 66% | 58%, 31%, 13%, and 74% of isolates were resistant to IMP, MEM, DOR and ERT, respectively. Thirty isolates were resistant to all carbapenems | • Large sample size | |||
| Aghamiri et al (2014) | Several hospitals in Tehran | General inpatients | Different sites | ✓ | • DD | 47% of isolates were resistant to IPM and all had an MIC >16 mcg/mL | |||||
| Nobari et al (2014) | Eight hospitals in Tehran | General inpatients | Different sites | • DD | Resistance rate to carbapenems was between 7% and 23% (66% of urine isolates were resistant to carbapenems) | ||||||
| Hakemi Vala et al (2014) | One hospital in Tehran | Burn patients | Burn wounds | ✓ | • CDT for MBL and ESBL detection | • 100% of | – | • Mortality rate was reported | |||
| Tavajjohi et al (2013) | One hospital in Kashan | General inpatients and environmental isolates | Different strains and wet environment | – | • DDST for ESBL detection | GEN 50% CIP 12% | • 8% of isolates were ESBL producers that | – | • Small sample size (only eight strains were evaluated for carbapenem resistance and genes) | ||
| Azimi et al (2013) | One hospital in Tehran (Motahari) | Burn patients | Burn wounds | • DD | – | • 64% of isolates were resistant to carbapenem | • Other antibiotics were not evaluated | – | |||
| Noori et al (2013) | Two hospitals in Mashhad | General inpatients | Wounds and respiratory secretions | • DDST for MBL production | CIP 100% | • All isolates were resistant to IPM and MEM | |||||
| Azimi et al(2013) | One hospital in Tehran | Burn patients | Not defined (probably burn wounds) | ✓ | • CDT for MBL detection | – | 85% of isolates were resistant to IPM that MIC range for them was 16–128 mcg/mL | ||||
| Pajand et al (2013) | Two hospitals in Tehran | Inpatients and burn patients | Burn wounds and other sites | ✓ | • DDST for MBL detection | Nonburn and burn patients: CIP 87%, 97% | Resistance rate to carbapenem in burn and nonburn patients was 98% and 68%, respectively | • Results of DDST were not reported | • Detection of OMP gene (carO) for evaluation of carbapenem resistance | ||
| Azami et al (2013) | Three hospitals in Tehran | General inpatients | Not defined | ✓ | • CDT for MBL detection | GEN 63% | • According to MIC, 53% of isolates were resistant to IPM and MIC values were ≥16 mcg/mL for IPM | • Few antibiotics were tested | • Assessment of integrin genes (genes for mobility of betalactamase) | ||
| Mohajeri et al (2013) | Three hospitals in Kermanshah | General inpatients | Sputum, blood, urine | – | • E-test for MBL detection | CIP 69%, GAT 43% | Resistance rate to carbapenems was 75%–80% | • MIC was not reported | • Multicenter study | ||
| Doosti et al (2013) | One hospital in Zanjan | General inpatients | Different sites | ✓ | • DD | CIP 40% | 63% of isolates were resistant to IPM that 41 of them had an MIC >4 mcg/mL | – | – | ||
| Shahcheraghi et al (2013) | Five hospitals in Tehran | General inpatients | Mostly urine and feces | Different strains (360) | – | • MHT | CIP 61.3% | • 6%, 3%, and 1% were resistant to MEM, ERT, and IPM, respectively | • MIC was not reported | • Multicenter study | |
| Kalantar et al (2012) | One hospital in Sanandaj | General inpatients | Different sites | ✓ | • DD | • 22 isolates were MBL positive and among them 8 isolates were resistant to IPM | |||||
| Shahcheraghi et al (2011) | Seven hospitals in Tehran | General inpatients | Different sites | ✓ | • DD | Of the 100 strains that were IPM resistant: CIP 84% AMK 84% | 49% and 100% of isolates were resistant to IPM and MEM, respectively | • Multicenter study | |||
| Peymani et al (2011) | One hospital in Tabriz | General inpatients | Different sites | – | • E-test for MBL detection | AMK 83% | About 55% of isolates were resistant to carbapenem | – | |||
| Saderi et al (2010) | One hospital in Tehran | General inpatients | Burn wounds | – | • CDT for MBL detection | GEN 86% | • 69% of isolates were resistant to IPM | • MIC was not determined | |||
| Yousefi et al (2010) | Two hospitals in Orumieh and Tabriz | General inpatients | Different sites | ✓ | • DDST for detection of MBL | CIP 83% | • Resistance rate to MEM was 86% | • Large sample size | |||
| Bahar et al (2010) | One hospital in Tehran (Motahari) | Burn patients | Burn wounds | – | • Disk inhibitor synergy test | It was not reported for all isolates (only reported in MBL producers) | • EDTA disk showed that 23 strains produced MBL and all had | • Large sample size | |||
| Khosravi et al (2008) | One hospital in Ahvaz | General inpatients | Different sites | – | • E-test for MBL detection | – | • Resistance rate to carbapenems was 41% | • FQ and AG were not tested | |||
| Yazdi et al (2007) | Two hospitals in Tehran | Not defined | Not defined | ✓ | • DD | – | According to MIC, resistance to IPM was 29% | • Few antibiotics were tested | – | ||
Notes:
MIC values for carbapenems (but not other antimicrobial agents) were considered.
Resistance rates were according to the result of disk diffusion test.
Results about blaOXA-51 were not provided because this gene has no correlation with occurrence of resistance, unless it has ISAba genes in its upstream.
For complete information about the resistance to AG and FQ, please refer to the original reference.
Abbreviations: AG, aminoglycoside; AMK, amikacin; BA, boronic acid; CDT, combination disk test; CIM, carbapenem inactivation method; CIP, ciprofloxacin; DD, disk diffusion; DDST, double disk synergy test; DOR, doripenem; ERT, ertapenem; ESBL, extended spectrum β-lactamase; FQ, fluoroquinolones; GAT, gatifloxacin; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; KAN, kanamycin; KPC, Klebsiella-producing carbapenemase; LVX, levofloxacin; MBL, metallo-β-lactamase; MCNP, modified CarbaNP; MEM, meropenem; MHT, modified Hodge test; MIC, minimum inhibitory concentration; NAL, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; PCR, polymerase chain reaction; TOB, tobramycin; BAL, Broncho Alveolar Lavage.
Figure 3Carbapenem-resistance rates in different areas of Iran (according to the disk diffusion method).
Notes: The data were extracted from the latest available studies. Multicenter studies from different cities were not considered for mapping due to pooled data. The studies in the special populations (ie, pediatrics or cystic fibrosis) and outpatients were excluded. *Reported resistance rates from Fars province were conflicting (13.7% in 2017 and 96% in 2016). §Data for Isfahan province were obtained from both Kashan (a city around Isfahan) and Isfahan itself, although the sample size for Isfahan was very small. ¶Data for Khorasan area were extracted from a study in 2015 with 36 strains. €Intermediate and absolute resistance rates were 25% and 2%, respectively. ¥Data in these provinces were for 2010–2014 studies.
Figure 4Carbapenem-resistant rates in different areas of Iran (according to the phenotypic and genotypic methods).
Notes: The data were extracted from the latest available studies. Multicenter studies from different cities were not considered for mapping due to pooled data. The studies in the special populations (ie, pediatrics or cystic fibrosis) and outpatients were excluded.
Some genes like blaSPM and blaSHV are mostly known as genes that encode ESBL enzymes, but they were included in this map, because these genes were assessed along with carbapenemase genes, and also overexpression of these genes concomitant with harboring efflux pump may be responsible for resistance to carbapenems. *Data for these five provinces were extracted from 2011 to 2014 articles, so new data are needed.
€Data were extracted from a 2015 study with 36 samples; another study in 2013 confirmed the presence of the genes of resistance in 4% of strains. ¥Data from Tehran province were conflicting; genes encoding resistance were detected in 15%–50% of isolates through 2015–2016. ¶Data from Kashan (a city in Isfahan province) showed presence of resistance genes in 80% of isolates in 2015.
§In Mazandaran and West Azerbaijan, these genes were reported, but rates of resistance were not included because the studies included different cities from different provinces. ① blaOXA-23 ② blaOXA-24 ③ blaOXA-58 ④ blaOXA-40 ⑤ blaOXA-48 ⑥ blaOXA-10 ⑦ blaOXA-143 ⑧ blaIMP ⑨ blaVIM ⑩ blaSPM ⑪ blaGES ⑫ blaPER ⑬ blaNDM ⑭ blaKPC ⑮ blaTEM ⑯ blaSHV ⑰ blaADC ⑱ blaSIM ⑲ blaGIM.
Abbreviations: ESBL, extended spectrum β-lactamase; KPC, Klebsiella-producing carbapenemase; MBL, metallo-β-lactamase.
Types of bla genes, first location of isolation, and the relevant microorganisms in Iran
| Ambler classes | Types of pf bla genes | First location of isolation | Year | Total genes | Microorganism |
|---|---|---|---|---|---|
|
| |||||
| GES | Tehran, by Shahcheraghi F. | 2011 | 12 | Mostly | |
| KPC | Tehran, by Nobari S. | 2014 | 61 | Mostly | |
|
| |||||
| NDM | Tehran, by Shahcheraghi F. | 2012 | 44 | Mostly | |
| VIM | Tehran, by Rezaei Yazdi H. | 2007 | 437 | Mostly | |
| IMP | Tabriz and Orumieh, byYousefi S. | 2010 | 271 | Mostly | |
| SIM | Tehran, By Maspi H. | 2016 | 2 | Only in | |
| GIM | Tehran, By Maspi H. | 2016 | 4 | Only in | |
|
| |||||
| OXA-23 | Tehran, by Taherikalani M. | 2008 | 1,287 | Only in | |
| OXA-24 | Tehran, by Taherikalani M. | 2008 | 213 | Only in | |
| OXA-58 | Tehran, by Taherikalani M. | 2008 | 96 | Only in | |
| OXA-40 | Tabriz, by Sohrabi N. | 2012 | 59 | Only in | |
| OXA-48 | Tehran, by Azimi L. | 2014 | 52 | In | |
| OXA-10 | Tehran, by Pakbaten S. | 2015 | 12 | Only in | |
| OXA-143 | Qom, by Sharikhani Z. | 2017 | 14 | Only in | |
Notes:
Year that the genes were isolated for the first time.
Total number of genes that were reported in Iranian studies.
The microorganisms in which the genes were isolated.